After a decade-long international research initiative involving 14,000 healthcare providers and patients, leading medical organizations have officially renamed polycystic ovary syndrome (PCOS) to polycystic ovary metabolic syndrome (PMOS). The change addresses longstanding diagnostic confusion stemming from the original terminology, which failed to accurately represent the condition’s broader pathophysiology.
The renaming effort, coordinated by Dr. Helena Teede at Monash University, recognizes that not all patients develop ovarian cysts and that PMOS encompasses significant metabolic dysfunction beyond reproductive manifestations. Clinical evidence increasingly demonstrates that the condition involves insulin resistance, cardiovascular risk factors, and metabolic complications requiring comprehensive, multidisciplinary management.
This nomenclature shift is expected to improve clinical recognition and patient outcomes globally, particularly in regions with high prevalence rates, including the Middle East and South Asia where estimates reach 11-13% among reproductive-aged women.
Read the full article on GMJ Newsroom.
Was this article helpful?
